Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00823147 · ClinicalTrials.gov registry record · Phase 1

Pain Catastrophizing as a Cause for Systemic Inflammation

A Phase 1 study of Musculoskeletal Pain, sponsored by Beth Darnall, PhD.

Completed
Registry status
Phase 1
Development phase
93
Enrollment target
1
Study location

NCT00823147 is a Phase 1 study of Musculoskeletal Pain that has completed, run by Beth Darnall, PhD. The registered enrollment target is 93 participants, below the 153-participant average among 37 other Musculoskeletal Pain trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00823147, a Phase 1 study of Musculoskeletal Pain, has completed, sponsored by Beth Darnall, PhD.

COMPLETED
Registry status
Phase 1
Development phase
93 participants
Enrollment target
1
Study location

Study Summary

Research shows that the immune system is involved in chronic pain. The immune system is involved in the process of inflammation. The investigators are still learning about the factors that cause inflammation, but know it can be measured in the blood. The purpose of this study is to understand how negative thoughts affect the immune system in women with chronic pain. A sub-study asks subjects to store a blood sample for future research by the PI aimed at identifying genetic markers in women with chronic pain.

Conditions Studied

Interventions

  • BEHAVIORAL Pain Catastrophizing Induction

Study Locations (1)

Oregon

  • Oregon Health and Science Universtiy - Portland

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2009-01
Est. Completion 2014-09
Phase Phase 1

Sponsor

Beth Darnall, PhD

1 total trials

What the Registry Record Tells You About NCT00823147

The ClinicalTrials.gov registry entry for NCT00823147 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 153-participant average among 37 other Musculoskeletal Pain trials with a reported enrollment target (39% lower). The listed sponsor is Beth Darnall, PhD, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Musculoskeletal Pain appearing as the primary indexed condition, and to 1 intervention - of which Pain Catastrophizing Induction is the first listed.

NCT00823147 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT00823147 about?

NCT00823147 is a clinical study titled "Pain Catastrophizing as a Cause for Systemic Inflammation". Research shows that the immune system is involved in chronic pain. The immune system is involved in the process of inflammation. The investigators are still learning about the factors that cause inflammation, but know it can be measured in the blood. The purpose of this study is to understand how ne...

What is the current status of trial NCT00823147?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 2009-01. Estimated completion is 2014-09.

What conditions does trial NCT00823147 study?

This clinical trial studies the following conditions: Musculoskeletal Pain.

What interventions are being tested in trial NCT00823147?

The interventions under investigation include: Pain Catastrophizing Induction (BEHAVIORAL).

Who is sponsoring clinical trial NCT00823147?

This trial is sponsored by Beth Darnall, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00823147 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Musculoskeletal Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.